CN107556387A - Resisting GPC 3 and the double targeting antibodies of CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application - Google Patents
Resisting GPC 3 and the double targeting antibodies of CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application Download PDFInfo
- Publication number
- CN107556387A CN107556387A CN201610514296.8A CN201610514296A CN107556387A CN 107556387 A CN107556387 A CN 107556387A CN 201610514296 A CN201610514296 A CN 201610514296A CN 107556387 A CN107556387 A CN 107556387A
- Authority
- CN
- China
- Prior art keywords
- specificity
- targeting antibodies
- gpc3
- cell
- double targeting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention provides the double targeting antibodies of a species specificity and its methods and applications.The first antigen-binding domains and specificity and the second antigen-binding domains of GPC3 antigen bindings that there is the double targeting antibodies of specificity specificity to be combined with mankind CD3, the tumour cell that can specifically identify and be overexpressed with reference to GPC3 antigens and GPC3, including positive tumor disease of liver cancer and other GPC3 etc., while it can also combine φt cell receptor；And mediate T cell plays lethal effect, so as to remove GPC3 infection, there is very big application value in diagnosis and treatment, prevention, detection GPC3 relevant diseases.Present invention also offers a kind of minicircle dna for the nucleotide sequence for having and encoding the double targeting antibodies of the specificity.The invention provides the double targeting antibodies of specificity and minicircle dna can be used for preparing antibody pharmaceutical compositions or GPC3 positive tumor cell diagnostic reagents.
Description
Technical field
The present invention relates to biological medicine and diagnosis and treatment field, and in particular to a kind of resisting GPC 3 and CD3 specificity pair targeting antibodies,
Minicircle dna and application containing this pair of targeting antibodies expression cassette.
Background technology
GPC3 (glypican-3) assignments of genes gene mapping in human chromosome Xq26.1 areas, the GPC3 albumen of coding
Relative molecular mass is about 70Kda, is made up of 580 amino acid.GPC3 core protein is made up of two parts, respectively
40kDa GPC3 aminoterminals (N-) fragment and 30kDa GPC3 c-terminuses (C-) fragment.1996, Pilia etc. first reported
There is undue growth syndrome (SGBS) in the patient of GPC3 gene mutations and afunction, and this is a kind of chain abnormal diseases of X
Disease, the undue growth of antenatal postpartum fetus is mainly shown as, and with the exception of extensive internal organ and bone, while can also increase
Add the tumorigenic possibility of embryo source property.Subsequent research shows that GPC3 mutation can cause Apoptosis and cell to increase again
That grows is out of proportion, and this is probably one of major reason of tumor development.GPC3 can also be with Heparin-binding type albumen phase
With reference to such as matrix components, cell adhesion molecule, enzyme and enzyme inhibitor, growth factor, participation adjust cell differentiation, propagation, glued
Physiology courses such as migration etc. are echoed, in addition, it may also participate in the mistake for adjusting a part of mesoderm tissues and allelotaxis
Journey.Then there is substantial amounts of research report to show that GPC3 is thin in hepatocellular carcinoma, malignant mela noma, Wilm's knurls, colorectal cancer, liver embryo
Born of the same parents' knurl and the high expression of neuroblastoma, and express in celiothelioma, breast cancer, adenocarcinoma of lung and oophoroma and significantly lower, carry
Show that GPC3 plays an important role in the occurrence and development of tumour.Main correlative theses (Eur J Cancer.2011Feb；47
(3):333-8.)。
In recent years, in immunotherapy of tumors field, occur using double targeting antibodies (Bispecific antibody,
BsAb) mediate T cell kills the new treatment of cancer cell.In human immune system, cytotoxic T lymphocyte (Cytotoxic T
Lymphocyte, CTL) important role is play, there is φt cell receptor (T cell receptor, TCR), can specificity knowledge
Not and target antigens expressed cell is combined, and secrete perforin and granzyme killing target cell.Tumour cell is exempted from due to lacking
The reason such as epidemic disease adhesion molecule and costimulatory molecules so that immunity of organism effectively can not be identified and activated, so that CTL can not be clear
Except cancer cell.BsAb can be simultaneously with T cell and tumor cell specific antigen binding, can be between T cell and tumour cell
Immunological synapse (immune synapse) is formed, the function of φt cell receptor (TCR) equally is played, so as to activate T cell immunization machine
System, mediate T cell kill target cell.
A kind of GPC3 antibody Codrituzumab is reported at present (also known as：1365267-33-9；RG7686；GC33；
Chugai anti-Glypican；RO5137382；GPC3；Glypican 3), by Chugai Pharmaceutical Co.,
Ltd.(Tokyo Japan)；Roche, F.Hoffmann-La Roche Ltd. (Basel Switzerland) are researched and developed, and are belonged to
Humanization IgG1-kappa antibody, the clinical II phases being currently in for primary carcinoma of liver test.But Codrituzumab can only
With reference to the positive cell of GPC3 antigens and GPC3 expression, it is impossible to, can not mediate T cell killing with reference to T cell；ADCC can only be passed through
Or GPC3 antigen positive tumour cells are killed in CDC targetings..
The present invention is intended to provide an efficient, inexpensive, resisting GPC 3 and the double targeting antibodies of CD3 specificity and preparation method thereof
And application.
The content of the invention
In a first aspect, the invention provides the double targeting antibodies of a species specificity, the double targeting antibodies of specificity have spy
The first antigen-binding domains and specificity and the second antigen binding structure of GPC3 antigen bindings that the opposite sex is combined with mankind CD3
Domain.
The invention provides the double targeting antibodies (Bispecific antibody, BsAb) of specificity, can simultaneously with
CD3 and GPC3 antigen bindings；Specifically identify simultaneously combine GPC3 antigen-positive cells, while also in relation with expression CD3 T cell,
Immunological synapse (immune synapse) can be formed between T cell and tumour cell, plays φt cell receptor (T cell
Receptor, TCR) the same function, so as to activate T cell immunologic mechanism, it is thin that mediate T cell plays killing GPC3 positive tumors
The effect of born of the same parents, so as to remove GPC3 positive tumor cells.
" double targetings " expression of the present invention " can simultaneously with CD3 and GPC3 antigen bindings ".
In an embodiment of the invention, the invention provides the double targeting antibodies of specificity, can be tied with CD3 and GPC3
Close；The double targeting antibodies of the specificity are also known as " the anti-anti- double targeting antibodies of GPC3 specificity of CD3/ " in the text." anti-CD3/ is anti-
The anti-GPC3 parts of the double targeting antibodies of GPC3 specificity " can be used for targeted expression GPC3 cell, such as HEPG2 liver cancer cell lines,
And the anti-CD3 parts of the double targeting antibodies molecules of specificity can be used for activating T cell.By with the GPC3 on GPC3 positive cells
Combined while with CD3 in T cell, promoting the T cell orientation of activation, to kill the GPC3 that (cell cracking) is targeted positive carefully
Born of the same parents.
The anti-double targeting antibodies of GPC3 specificity of anti-CD3/ of the present invention, it is especially, positive swollen for diagnosing, treating GPC3
Oncocyte, and the physiology of the unconventionality expression initiation for the treatment of, prevention and/or control with GPC3 unconventionality expression and/or by GPC3
Disorderly method and composition.Such disorder includes but is not limited to:Cancer, non-cancer hyperproliferative cell are disorderly.
The double targeting antibodies of exemplary specificity of the present invention are listed in the Tables 1 and 2 in text.Specificity provided by the invention is double
In targeting antibodies, weight chain variable district (HCVR) that the first antigen-binding domains and the second antigen-binding domains include and light
Chain variable region (LCVR)).The table 2 of table 1 lists HCVR, LCVR of the double targeting antibodies of specificity provided by the invention amino acid sequence
Row, and its sequence number in sequence table.Table 2 is listed corresponding to coding HCVR, LCVR amino acid sequence of the present invention
Nucleotide sequence, and its sequence number in sequence table.
The amino acid sequence of the double targeting antibodies of specificity provided by the invention includes：At least one the first antigen binding structures
It is the HCVR amino acid sequences in domain, the LCVR amino acid sequences of at least one the first antigen-binding domains, at least one the second anti-
The LCVR amino acid sequences of the HCVR amino acid sequences of former binding structural domain and at least one the second antigen-binding domains；
Specific HCVR and LCVR is preferably any amino acid sequence selected from table 1.
Encoding the nucleotide sequence of the double targeting antibodies of specificity provided by the invention includes：At least one the first antigen bindings
The HCVR nucleotide sequences of domain, the LCVR nucleotide sequences of at least one the first antigen-binding domains, at least one the
The LCVR nucleotides sequences of the HCVR nucleotide sequences of two antigen-binding domains and at least one the second antigen-binding domains
Row；Specific HCVR and LCVR is preferably any nucleotide sequence selected from table 2.
Amino acid sequence in the sequence table of table 1
In an embodiment of the present invention, 3 not homotactic anti-CD3 × double targeting antibodies of anti-GPC3 specificity, in table 1
Middle numbering is respectively BsAb-1, BsAb-2, BsAb-3, and wherein BsAb-1 is the double targets of specificity of the optimum efficiency by filtering out
To antibody.
In some embodiments of the invention, 1 each sequence of table is specially：
In SEQUENCE NO.1,
CD3.HCVR
QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGRVNPNRRGTTYNQKFEGRVTMTTDTSTS
TAYMELRSLRSDDTAVYYCARANWLDYWGQGTTVTVSS；
In SEQUENCE NO.2,
CD3.LCVR
DIQMTQSPSSLSASVGDRVTITCSVSSSVSSIYLHWYQQKPGKAPKLLIYSTSNLASGVPSRFSGSGSGTDFTLTIS
SLQPEDFATYYCQVYSGYPLTFGGGTKVEIK；
In SEQUENCE NO.3,
GPC3-HCVR
EVQLVETGGGMVQPEGSLKLSCAASGFTFNKKAMNWVRQAPGKGLEWVARIRNKTNNYATYYADSVKARFTISRDDS
QSMLYLQMNNLKIEDTAMYYCVAGNSFAYWGQGTLVTVSA；
In SEQUENCE NO.4,
GPC3-LCVR
DIVMSQSPSSLVVSIGEKVTMTCKSSQSLLYSSNQKNYLAWYQQKPGQSPKLLIYWASSRESGVPDRFTGSGSGTDF
TLTISSVKAEDLAVYYCQQYYNYPLTFGAGTKLELK；
In SEQUENCE NO.5,
GPC3-HCVR
EVQLVETGGGMVQPEGSLKLGCAASGFTFNRKAMNWVRQAPGKGLEWVARIRNKTNNYATYYADGVRARFTLSRDDS
QSMLYLQMNNLKLEDTAMYYCVAGNSFAYWGQGTLVTVSA；
In SEQUENCE NO.6,
GPC3-LCVR
DIVMSQSPSGLVVSIGEKVTMTCKGSQSLLYSSNQKNYLAWYQQKPGQSPKLIIYWASSRESGVPDKFTGSGSGTDF
TLTISGVKAEDLAVYYCQQYYNYPLTFGAGTKLELK；
In SEQUENCE NO.7,
GPC3-HCVR
EVQLVETGSGMVQPEGSLKISCAASGFTFNKKAMNWVRQAPGRGLEWVARIRNKTNNYATYYADGVKARFTISRDDS
QSMLYLQMNNLKLEDTAMYYCVAGNSFAYWGQGTLVTVSA；
In SEQUENCE NO.8,
GPC3-LCVR
DIVMSQSPSGLVVSIGEKVTMTCKSSQSLIYSSNQKNYLAWYQQKPGQSPKLLIYWASGRESGVPDRFTGSGSGTDF
TLTLSGVKAEDLAVYYCQQYYNYPLTFSAGTKLELK；
Nucleotide sequence in the sequence table of table 2
In some embodiments of the invention, 2 each sequence of table is specially：
SEQUENCE NO.9,
CD3.HCVR
CAGGTTCAGCTGGTGCAGTCTGGTGCTGAGGTGAAGAAGCCTGGTGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGG
TTACACATTCACTGACTACTACATGCACTGGGTGAGACAGGCCCCTGGTCAAGGTCTTGAGTGGATGGGTAGAGTTA
ATCCTAACCGGAGGGGTACTACCTACAACCAGAAATTCGAGGGCCGTGTCACCATGACCACAGACACATCCACCAGC
ACAGCCTACATGGAGCTGCGTAGCCTGCGTTCTGACGACACCGCCGTGTATTACTGCGCCCGTGCTAACTGGCTTGA
CTACTGGGGCCAGGGCACCACCGTCACCGTCTCCTCC；
SEQUENCE NO.10,
CD3.LCVR
CAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTTGGAGACAGAGTCACCATCACTTGCAGTGTCAGCTCAAG
TGTTTCCTCCATTTACTTGCACTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATAGCACATCCA
ACTTGGCTTCTGGAGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTG
CAACCTGAAGATTTTGCAACTTACTACTGCCAAGTCTACAGTGGTTACCCTCTCACCTTCGGCGGAGGGACCAAGGT
GGAGATCAAA；
In SEQUENCE NO.11,
GPC3-HCVR
GAGGTGCAGCTGGTGGAGACCGGCGGCGGCATGGTGCAGCCCGAGGGCAGCCTGAAGCTGAGCTGCGCCGCCAGCGG
CTTCACCTTCAACAAGAAGGCCATGAACTGGGTGCGCCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCCGCATCC
GCAACAAGACCAACAACTACGCCACCTACTACGCCGACAGCGTGAAGGCCCGCTTCACCATCAGCCGCGACGACAGC
CAGAGCATGCTGTACCTGCAGATGAACAACCTGAAGATCGAGGACACCGCCATGTACTACTGCGTGGCCGGCAACAG
CTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCC；
In SEQUENCE NO.12,
GPC3-LCVR
GACATCGTGATGAGCCAGAGCCCCAGCAGCCTGGTGGTGAGCATCGGCGAGAAGGTGACCATGACCTGCAAGAGCAG
CCAGAGCCTGCTGTACAGCAGCAACCAGAAGAACTACCTGGCCTGGTACCAGCAGAAGCCCGGCCAGAGCCCCAAGC
TGCTGATCTACTGGGCCAGCAGCCGCGAGAGCGGCGTGCCCGACCGCTTCACCGGCAGCGGCAGCGGCACCGACTTC
ACCCTGACCATCAGCAGCGTGAAGGCCGAGGACCTGGCCGTGTACTACTGCCAGCAGTACTACAACTACCCCCTGAC
CTTCGGCGCCGGCACCAAGCTGGAGCTGAAG；
In SEQUENCE NO.13,
GPC3-HCVR
GAGGTGCAGCTGGTGGAGACCGGCGGCGGCATGGTGCAGCCCGAGGGCAGCCTGAAGCTGGGCTGCGCCGCCAGCGG
CTTCACCTTCAACCGCAAGGCCATGAACTGGGTGCGCCAGGCCCCCGGCAAGGGCCTGGAGTGGGTGGCCCGCATCC
GCAACAAGACCAACAACTACGCCACCTACTACGCCGACGGCGTGCGCGCCCGCTTCACCCTGAGCCGCGACGACAGC
CAGAGCATGCTGTACCTGCAGATGAACAACCTGAAGCTGGAGGACACCGCCATGTACTACTGCGTGGCCGGCAACAG
CTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCC；
In SEQUENCE NO.14,
GPC3-LCVR
GACATCGTGATGAGCCAGAGCCCCAGCGGCCTGGTGGTGAGCATCGGCGAGAAGGTGACCATGACCTGCAAGGGCAG
CCAGAGCCTGCTGTACAGCAGCAACCAGAAGAACTACCTGGCCTGGTATCAGCAGAAGCCCGGCCAGAGCCCCAAGC
TGATCATCTACTGGGCCAGCAGCCGCGAGAGCGGCGTGCCCGACAAGTTCACCGGCAGCGGCAGCGGCACCGACTTC
ACCCTGACCATCAGCGGCGTGAAGGCCGAGGACCTGGCCGTGTACTACTGCCAGCAGTACTACAACTACCCCCTGAC
CTTCGGCGCCGGCACCAAGCTGGAGCTGAAG；
In SEQUENCE NO.15,
GPC3-HCVR
GAGGTGCAGCTGGTGGAGACCGGCAGCGGCATGGTGCAGCCCGAGGGCAGCCTGAAGATCAGCTGCGCCGCCAGCGG
CTTCACCTTCAACAAGAAGGCCATGAACTGGGTGCGCCAGGCCCCCGGCCGCGGCCTGGAGTGGGTGGCCCGCATCC
GCAACAAGACCAACAACTACGCCACCTACTACGCCGACGGCGTGAAGGCCCGCTTCACCATCAGCCGCGACGACAGC
CAGAGCATGCTGTACCTGCAGATGAACAACCTGAAGCTGGAGGACACCGCCATGTACTACTGCGTGGCCGGCAACAG
CTTCGCCTACTGGGGCCAGGGCACCCTGGTGACCGTGAGCGCC；
In SEQUENCE NO.16,
GPC3-LCVR
GACATCGTGATGAGCCAGAGCCCCAGCGGCCTGGTGGTGAGCATCGGCGAGAAGGTGACCATGACCTGCAAGAGCAG
CCAGAGCCTGATCTACAGCAGCAACCAGAAGAACTACCTGGCCTGGTATCAGCAGAAGCCCGGCCAGAGCCCCAAGC
TGCTGATCTACTGGGCCAGCGGCCGCGAGAGCGGCGTGCCCGACCGCTTCACCGGCAGCGGCAGCGGCACCGACTTC
ACCCTGACCCTGAGCGGCGTGAAGGCCGAGGACCTGGCCGTGTACTACTGCCAGCAGTACTACAACTACCCCCTGAC
CTTCAGCGCCGGCACCAAGCTGGAGCTGAAG；
Specifically, SEQUENCE NO.9-16 correspond to coding SEQUENCE NO.1-8 amino acid sequence respectively.
In view of sequence homology, it will be appreciated by persons skilled in the art that scheme, which is implemented as follows, should include guarantor of the present invention
Protect scope：
In some embodiments of the invention, the HCVR of the first described antigen-binding domains is and the shown in table 1
Any HCVR amino acid sequences have at least 90%, at least 95%, at least 98% or at least 99% in one antigen-binding domains
The amino acid sequence of homology.
In some embodiments of the invention, the LCVR of the first described antigen-binding domains is and the shown in table 1
Any LCVR amino acid sequences have at least 90%, at least 95%, at least 98% or at least 99% in one antigen-binding domains
The amino acid sequence of homology.
In some embodiments of the invention, the HCVR of the second described antigen-binding domains is and the shown in table 1
Any HCVR amino acid sequences have at least 90%, at least 95%, at least 98% or at least 99% in one antigen-binding domains
The amino acid sequence of homology.
In some embodiments of the invention, the LCVR of the second described antigen-binding domains is and the shown in table 1
Any LCVR amino acid sequences have at least 90%, at least 95%, at least 98% or at least 99% in one antigen-binding domains
The amino acid sequence of homology.
In some embodiments of the invention, described the first antigen-binding domains of coding HCVR sequence be with table 2
In the first shown antigen-binding domains any HCVR nucleotide sequences have at least 90%, at least 95%, at least 98% or
At least nucleotide sequence of 99% homology.
In some embodiments of the invention, described the first antigen-binding domains of coding LCVR sequence be with table 2
In the first shown antigen-binding domains any LCVR nucleotide sequences have at least 90%, at least 95%, at least 98% or
At least nucleotide sequence of 99% homology.
In some embodiments of the invention, described the second antigen-binding domains of coding HCVR sequence be with table 2
In the first shown antigen-binding domains any HCVR nucleotide sequences have at least 90%, at least 95%, at least 98% or
At least nucleotide sequence of 99% homology.
In some embodiments of the invention, described the second antigen-binding domains of coding LCVR sequence be with table 2
In the first shown antigen-binding domains any LCVR nucleotide sequences have at least 90%, at least 95%, at least 98% or
At least nucleotide sequence of 99% homology.
It should be understood that there is base degeneracy because of situations such as " nucleotide sequence ", be mutated, those of ordinary skill in industry
The species of some bases is can adjust, although described base change result in the change of codon, but not causes codon to turn over
The change for the amino acid translated, very common, the codon of leucine just has a variety of codons, such as：UUA、UUG、CUU.
In addition, EpCAM antibody amino acids sequences of the present invention come from human antibody amino acid sequence, by messenger
HVGR (host versus graft reaction, HVGR) can be reduced in body application.Nucleotide sequence passes through
Codon optimization is crossed, is expressed beneficial in mammalian cell.
In some embodiments of the invention, the amino acid sequence of the double targeting antibodies of specificity is：Optionally from table 1
Sequence, it is a kind of combination gained (" V in (a)~(h) by following type of attachmentLCD3 " represents the double targeting antibodies of specificity
The LCVR of first antigen-binding domains；“VHCD3 " represents the first antigen-binding domains of the double targeting antibodies of specificity
HCVR；“VLGPC3 " represents the LCVR of the second antigen-binding domains of the double targeting antibodies of specificity；“VHGPC3 " represents specificity
The HCVR of second antigen-binding domains of double targeting antibodies)：
(a)VLGPC3-linker1-VHGPC3-linker2-VLCD3-linker3-VHCD3,
(b)VHGPC3-linker1-VLGPC3-linker2-VLCD3-linker3-VHCD3,
(c)VLGPC3-linker1-VHGPC3-linker2-VHCD3-linker3-VLCD3,
(d)VHGPC3-linker1-VLGPC3-linker2-VHCD3-linker3-VLCD3,
(e)VLCD3-linker1-VHCD3-linker2-VLGPC3-linker3-VHGPC3,
(f)VLCD3-linker1-VHCD3-linker2-VHGPC3-linker3-VLGPC3,
(g)VHCD3-linker1-VLCD3-linker2-VLGPC3-linker3-VHGPC3,
(h)VHCD3-linker1-VLCD3-linker2-VHGPC3-linker3-VLGPC3,
Wherein, whippletree "-" represents each amino acid sequence order and arranged.
In an embodiment of the invention, the HCVR (V of the first antigen-binding domains or the second antigen-binding domainsH)
With LCVR (VL) between Linker (Linker1, Linker3) amino acid sequence be (GGGGS) n (n=1-4), (GGS) 4
Or (Gly) n (n=6-8), but not limited to this.
In an embodiment of the invention, the amino acid sequence of the Linker (Linker2) between each antigen-binding domains
It is classified as (GGGGS) n (n=1-4), but not limited to this.
In a preferred embodiment, bispecific single-chain antibody amino acid sequence is with any with (a)~(h)
The homology of shown sequence is not less than 90%, 95%, 98% or 99% amino acid sequence.
In some embodiments of the invention, the HCVR (V of each antigen-binding domainsH) and LCVR (VL) between, each antigen knot
It is connected between conjunction domain by linker, Linker is connection peptide, and the connection peptide is mainly employed with glycine and serine
Based on the peptide sequence that forms, wherein, glycine is the amino acid that molecular weight is minimum, side chain is most short, can increase the flexible of side chain
Property；Serine is the most strong amino acid of hydrophily, can increase the hydrophily of peptide chain.
In some embodiments of the invention, the N sections of the double targeting antibodies of specificity have immunoglobulin kappa chain signal peptide
Amino acid sequence.
The N-terminal of the double targeting antibodies of the specificity provided by the invention adds the secretion letter of light chain immunoglobulin κ chains
Number peptide, so as to ensure the expression of antibody and be secreted into outside host cell.
Second aspect, present invention also offers a kind of side of the double targeting antibodies of the specificity prepared as described in relation to the first aspect
Method, this method include：The specificity that the double targeting antibodies sequences of specificity described in first aspect are used for described in construction expression is double
The recombinant expression carrier of targeting antibodies；Import host cell；Under expression condition, host cell is cultivated, expression, is isolated and purified,
Obtain the double targeting antibodies of the specificity.
The third aspect, present invention also offers the double targeting antibodies of specificity as described in relation to the first aspect by following a kind of or more
Kind method is applied：
(1) the double targeting antibodies of the specificity are individually applied；
(2) by the double targeting antibodies of specificity and one kind in chemotherapy, radiotherapy, operation, biological therapy, immunization therapy or
Several use in conjunction；
(3) the double targeting antibodies of the specificity are directly delivered into patient's body by the way of delivering in vivo to be controlled
Treat；
(4) first pass through in-vitro transfection technology to mix the double targeting antibodies of the specificity with immune effector cell, then will
Described defeated time patient's body of immune effector cell for being mixed with specific double targeting antibodies implements treatment.
In some embodiments of the invention, in the application (3) and (4) as described in the third aspect, as above institute is applied to patient
The antibody stated, it can be applied more than once to patient.
In some embodiments of the invention, in the application (3) as described in the third aspect, the mode of described delivery is targeting
Deliver, including but not limited to using can the industry common carrier such as liposome liposomes (or its polymer) of targeting Delivery carry out
Deliver.
By applying the antibody of first aspect present invention offer or the medicine of fourth aspect offer to the mammal including people
Compositions, it can prevent or treat liver cancer or other GPC3 relevant disease, such as GPC3 abnormal expressions or disorderly related disease
Disease.
Fourth aspect, the invention provides a kind of pharmaceutical composition, including at least one as described in relation to the first aspect special
Property double targeting antibodies, and pharmaceutically useful supporting agent, excipient or diluent.
Pharmaceutical preparation can be made according to conventional methods for pharmaceutical composition provided by the invention., preferably will be anti-in production process
Body is mixed with carrier or diluted with carrier, or is fitted into the carrier of vessel form.When the carrier serves as a diluent, it can be solid
Body, semisolid or liquid, as the vesica, excipient or culture medium for antibody.Therefore, preparation can be tablet, pill, powder
Agent, sachet, capsule, elixir, supensoid agent, emulsion, solution, syrup, aerosol, soft hard gelatin capsule, injection without
The forms such as bacterium solution, sterile powder.The example of suitable carrier, excipient or diluent includes lactose, glucose, sucrose, mountain
Pears alcohol, mannitol, calcium silicates, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, hydroxybenzoic acid
Methyl esters, nipasol, talcum powder, magnesium stearate and mineral oil.Preparation can also include filler, anticoagulant, profit
Lubrication prescription, wetting agent, flavor enhancement, emulsifying agent, preservative etc..
In some embodiments of the invention, described pharmaceutical composition also includes second therapeutic agent, and second therapeutic agent is to appoint
The activating agent what is advantageously combined with the double targeting antibodies of described specificity.Including but not limited to combine and/or activate CD3 signals
Other activating agents (including other antibody or its antigen-binding fragment etc.) transmitted, and/or it is not direct combined with CD3, but live
Change or stimulate the activating agent of activated immune cell.
In some embodiments of the invention, described second therapeutic agent includes and the agent interfering of antibody synergy, anti-
GPC3 monoclonal antibodies, resisting GPC 3 polyclonal antibody, nucleoside analog, archaeal dna polymerase inhibitor, siRNA preparations, as disease-resistant
The treatment vaccine of toxic agent, cell factor, toxin, chemotherapeutant, radiotherapy dose, hormone, antibody Fc fragment, TLR excitements
Agent, molecule or co-stimulators containing CpG.
5th aspect, the invention provides a kind of diagnostic reagent, including at least one specificity as described in relation to the first aspect
Double targeting antibodies, and diagnosticum, described diagnosticum include but is not limited to fluorogen, chromophore, dyestuff, radio isotope,
Chemiluminescent molecule, paramagnetic ion or spin trapping reagent.
6th aspect, the invention provides a kind of antibody drug, for the double targetings of any specificity as described in relation to the first aspect
Antibody, it is incorporated in external evoked mankind's T cell with mankind CD3 knots and breeds.
7th aspect, the invention provides a kind of antibody drug, for the double targetings of any specificity as described in relation to the first aspect
Antibody, being killed to GPC3 positive cells for external evoked T cell mediation is incorporated in mankind CD3 knots.
Eighth aspect, the invention provides a kind of nucleic acid molecules, the double targetings of specificity encoded as described in relation to the first aspect are anti-
The amino acid sequence of body；In some embodiments, the amino acid sequence of described nucleic acid molecule encoding, it is and such as first aspect
The amino acid sequence of the double targeting antibodies of specificity has at least 90%, at least 95%, at least 98% or at least 99% homologous
The amino acid sequence of property.
9th aspect, the invention provides a kind of restructuring load of the double targeting antibodies of the specificity expressed as described in relation to the first aspect
Body；In some embodiments, described recombinant vector has any sequence of nucleic acid molecules that eighth aspect present invention provides.
In some embodiments of the invention, described carrier is that minicircle dna recombinates matrix grain or minicircle dna.
In some embodiments of the invention, the minicircle dna restructuring matrix grain is in the polyclonal position of minicircle dna empty plasmid
Any sequence of nucleic acid molecules that eighth aspect present invention provides is inserted in point to combine.Specific insertion method can use conventional
Gene cloning, it can also use seamless clone (Seamless cloning).
In some embodiments of the invention, the minicircle dna empty plasmid is preferably p2 Ф C31 plasmids or pMC.BESPX matter
Grain.Specifically, the empty plasmid p2 Ф C31 construction methods are with reference to Chen ZY etc., Molecular Therapy, 8 (3), 495-
500 (2003), Chen ZY etc., Human Gene Therapy, 16 (1), 126-131 (2005) and United States Patent (USP)
US7897380B2.Specifically, described empty plasmid pMC.BESPX construction methods and complete genome sequence reference Chen ZY etc.,
Nature Biotechnology,28,(12),1289-1291(2010)。
The p2 Ф C31 weights that p2 Ф C31 plasmids, the pMC.BESPX plasmids used in exemplary embodiments of the present invention obtains respectively
Group matrix grain, pMC.BESPX restructuring matrix grains, difference are：There is coding Ф C31 recombinases and I- on p2 Ф C31 carriers
The nucleotide sequence of Sce1 restriction endonucleases, and there is no the core for encoding Ф C31 recombinases and I-Sce1 restriction endonucleases on pMC.BESPX carriers
Nucleotide sequence, thus using pMC.BESPX carriers prepare minicircle dna matrix grain it is more high-quality, greatly reduce recombinase and
The pollution of the nucleotide sequence of restriction endonuclease；But pMC.BESPX need to support the use E. coli ZYCY10P3S2T
Engineering bacteria, ZYCY10P3S2T engineering bacterias have coding Ф C31 recombinases and I-Sce1 restriction endonuclease functions, no Ф C31 recombinases
The pMC.BESPX of (i.e. phiC31 groups enzyme) and I-Sce1 restriction endonuclease nucleotide coding sequences restructuring matrix grains need to support the use
ZYCY10P3S2T engineering bacterias could produce internal locus specificity restructuring (and E. coli TOP 10 is without this function)
And final production goes out minicircle dna；Accordingly, p2 Ф C31 restructuring matrix grain, which can support the use TOP 10, can produce internal site
Specificity restructuring, and final production goes out minicircle dna.
In some embodiments of the invention, described minicircle dna is that minicircle dna provided by the invention restructuring matrix grain passes through
The locus specificity restructuring of specific recombination site produces.Minicircle dna restructuring matrix grain provided by the invention has specificity weight
Group site, described " minicircle dna restructuring matrix grain " produce minicircle dna by the locus specificity restructuring of specific recombination site
With skeleton DNA sequence dna.The method of p2 Ф C31 restructuring matrix grain production minicircle dnas is with reference to Chen ZY etc., Molecular
Therapy, 8 (3), 495-500 (2003), Chen ZY etc., Human Gene Therapy, 16 (1), 126-131 (2005) and
United States Patent (USP) US7897380B2.The method of pMC.BESPX restructuring matrix grain production minicircle dnas is with reference to Chen ZY etc., Nature
Biotechnology,28,(12),1289-1291(2010)。
As used herein, " skeleton DNA sequence dna " there is the duplication for being responsible for bacterial plasmid in standard plasmid or screening to contain plasmid
The function such as host DNA sequence dna, such as bacterium replication sequence, resistant gene, unmethylated CpG motifs etc..
In some embodiments of the invention, described recombinant vector (is special in the present invention also comprising expression desired polypeptides
Property double targeting antibodies) needed for all necessary elements gene expression system, generally it include elements below：Promoter, coding
The gene order of polypeptide, terminator；Additionally alternative is including signal coding sequence etc.；These elements are to be operatively connected
's.
As used herein, described " being operably connected " refers to two or more nucleic acid regions or the function of nucleotide sequence
The space arrangement of property.Such as：Promoter region is placed in the ad-hoc location relative to target gene nucleotide sequence so that nucleotide sequence
Transcription guided by the promoter region, so as to, promoter region is " operably connected " on the nucleotide sequence.It is excellent
Selection of land, the signal peptide are immunoglobulin kappa chain signal peptide.Preferably, the label is His labels, GST labels, c-myc marks
At least one of label and Flag labels.Signal peptide above and the preferred embodiment that tag class is the present inventor, this area skill
Art personnel can select suitable signal peptide and label according to specific needs.
Tenth aspect, the invention provides a kind of host cell (preferably eucaryon with the carrier as described in terms of the 9th
Cell or mammalian cell including people)；Additionally provide in the vector introduction host cell as described in terms of the 9th
Method；Additionally provide by host cell of the culture with the carrier under conditions of generation antibody is allowed, and separating force institute
The method of caused antibody.
Tenth on the one hand, and the invention provides a kind of detection kit, including solid detection holder, the inspection of described solid
Survey holder and include the double targeting antibodies of at least one specificity as described in relation to the first aspect.In some embodiments, it is described solid
Body holder is the surface of solids that can connect macromolecular such as antibody, protein, polypeptide, peptide, polynucleotides, such as magnetic beads, latex
Pearl, micro titer plate well, glass plate, nylon, agarose, polyacrylamide, silica dioxide granule, nitrocellulose filter etc..
12nd aspect, the invention provides a kind of method that abnormal cell is detected in testing sample, it includes making institute
Sample is stated to be in contact with the double targeting antibodies of at least one specificity as described in relation to the first aspect.In some embodiments, it is described
Tumor bed of the sample from liver or through excision.
As described herein, " abnormal cell " be have for the cell type be atypical characteristics (including atypia give birth to
The long, typical growth of atypia opening position or the typical effect for atypia target) any cell.Such cell includes
Cancer cell, hyperplasia of prostate cell or dysplasia cell, inflammatory cell or autoimmunity cell.
In some embodiments of the invention, using the method as described in terms of the 12nd to the tissue or device donated before transplanting
Official is screened, to provide the tissue or organ that are substantially free of GPC3.
In some embodiments of the invention, blood supply product are screened using the method as described in terms of the 12nd,
To provide the blood supply product for being substantially free of GPC3.
13rd aspect, double targeting antibodies of specificity as described in relation to the first aspect or the recombinant vector as described in terms of the 9th
Preparing diagnosis, preventing, the application in the reagent or medicine for the treatment of GPC3 relevant diseases.
As described in the present invention, described " GPC3 diseases " includes but is not limited to GPC3 abnormal expressions or disorderly related disease
Disease, such as, the liver cancer of GPC3 antigen positives.
Fourteenth aspect, present invention also offers using the double targeting antibodies treating cancers of specificity as described in relation to the first aspect
Or the method for tumour, include following methods any one：
(1) genetic engineering antibody is individually used for treating cancer or tumour；
(2) by the one or more in the genetic engineering antibody and chemotherapy, radiotherapy, operation, biological therapy, immunization therapy
Combine and be used for treating cancer or tumour；
(3) genetic engineering antibody is directly delivered to patient's body by the way of internal targeting Delivery and carries out cancer
Or oncotherapy；
(4) first pass through in-vitro transfection technology to mix the genetic engineering antibody with immune effector cell, then by described in
The defeated time patient's body of immune effector cell for being mixed with genetic engineering antibody implements cancer or oncotherapy.
In some embodiments of the invention, in methods described (4), the immune effector cell is that CIK cell or D-CIK are thin
Born of the same parents.
In some embodiments of the invention, in methods described (4), the double targeting antibodies of specificity of described first aspect with
Immune effector cell mixing ratio be：0.001~1ug/ul double the targeting antibodies and 1 × 10 of specificity4~1.6 × 105It is immune
Effector cell mixes.
Technical scheme provided by the invention, by designing the double targeting antibodies of a group-specific, and by antibody expression frame (DNA
Sequence) insertion minicircle dna carrier (preferably Kay MA*, He CY and Chen ZY* (* communicates author) .A Robust
system for production of minicircle DNA vecrtors.Nat Biotechnology,28:1287,
2010) in.The antibody expressed by minicircle dna has following characteristic：1) GPC3 positive antigens are specifically bound；2) specifically bind
T cell；3) mediate T cell plays lethal effect to GPC3 antigen-positive cells.In addition, in certain embodiments, due to antibody
Expression cassette carries the coded sequence of secreting signal peptide, can be secreted after antibody expression to extracellular, holding bioactivity.
Brief description of the drawings
Fig. 1 is the plasmid map of micro-loop matrix grain prepared by the embodiment of the present invention 1；
Fig. 2 is the plasmid map of minicircle dna prepared by the embodiment of the present invention 2；
Fig. 3 is that the Western Blot that the embodiment of the present invention 3 provides detect BsAb antibody expressions in culture medium supernatant
Result；
Fig. 4-5 is GPC3 × CD3BsAb cell binding experiments flow cytomery knots that the embodiment of the present invention 4 provides
Fruit；Wherein, a-b represents BsAb-1, BsAb-2 result respectively；B is BsAb result, and C is control (control)；
The sample-adding packet for GPC3 × CD3BsAb joint DCIK cell killings experiments that Fig. 6-7 embodiment of the present invention 5 provides and
As a result.
Embodiment
As described below is the preferred embodiment of the present invention, it is noted that for those skilled in the art
For, under the premise without departing from the principles of the invention, some improvements and modifications can also be made, these improvements and modifications are also considered as
Protection scope of the present invention.
Outer without special instruction in the embodiment of the present invention, agents useful for same and consumptive material are commercial goods.
Embodiment 1
The structure of micro-loop matrix grain with coding GPC3 × CD3BsAb antibody nucleotide sequences, comprises the following steps：
1) BsAb antibody gene expression cassettes are designed
The BsAb antibody genes expression cassette of the embodiment of the present invention 1 also wraps in addition to the nucleotide sequence containing coding BsAb
Include promoter, secreting signal peptide, protein purification label, the coded sequence of polyA tailing signals.
In an embodiment, the BsAb antibody genes expression cassette of the embodiment of the present invention 1 includes what is be sequentially connected：
Nucleotide sequence (the Murine Ig kapa-chain signal of encoding immune globulin κ chain signal peptides
Peptide, SEQ ID NO:17) gene order (V of-BsAb antibodyLGPC3-linker1-VHGPC3-linker2-VHCD3-
linker3-VLCD3；GPC3LCVR-linker1-GPC3HCVR-linker2- in specific nucleotide sequence corresponding table 2
Nucleotide sequence (the SEQ ID NO of CD3HCVR-linker3-CD3LCVR- encoding histidine 6-His labels:18)-dual end
Only codon (TAGTGA)；Wherein,
The nucleotide sequence of encoding immune globulin κ chain signal peptides, such as SEQ ID NO:Shown in 17.
The nucleotide sequence of encoding histidine 6-His labels, such as SEQ ID NO:Shown in 18.
The BsAb antibody genes expression cassette of the embodiment of the present invention 1 also includes the nucleotides sequence of cytomegalovirus CMV promoter
Row, positioned at the N sections of Signal peptide secreting signal peptides；Sequence is SEQ ID NO:19.
The BsAb antibody genes expression cassette of the embodiment of the present invention 1 also includes bovine growth hormone polynucleotide poly A (BGH
Poly A) nucleotide sequence, positioned at terminator codon (TGATAG) C-terminal；Sequence is SEQ ID NO:20.
In order to strengthen the expression efficiency of minicircle dna carrier, element chimeric intron are with the addition of (between CMV promoter
Between Signal peptide secreting signal peptides；Document report, 10-20 times can be strengthened in various kinds of cell), sequence SEQ
ID NO:21。
In the BsAb antibody gene expression cassettes of the embodiment of the present invention 1, linker1, linker2 amino acid sequence are identical,
It is (GGGGS)3, nucleotide sequence is different, nucleosides shown in respectively SEQUENCE NO.22 and SEQUENCE NO.23
Acid sequence.
Linker3 amino acid sequences are VEGGSGGSGGSGGSGGVD, and nucleotides sequence is classified as shown in SEQUENCE NO.24
Nucleotide sequence.
Specifically, each sequence is as follows：
In SEQUENCE NO.17,
Murine Ig kapa-chain signal peptide
ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTTCCAGGTTCCACTGGT；
In SEQUENCE NO.18,
6-His
CATCATCACCATCATCAT；
In SEQUENCE NO.19,
CMV promoter
GTCAATATTGGCCATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACG
TTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGGCATTGATTATTGAC
TAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGG
TAAATGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACG
CCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTA
TCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTATGCCCAGTACATGACCT
TACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTAC
ACCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTT
TTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGGTAGGCGTG
TACGGTGGGAGGTCTATATAAGCAGAGGTCGTTTAGTGAACCGTCAGATCACTAGTAGCTTTATTGCGGTAGTTTAT
CACAGTTAAATTGCT；
In SEQUENCE NO.20,
BGH poly A
GGTGATCAGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCCTCCCCCGTGCCTTCCTTGACCCTG
GAAGGTGCCACTCCCACTGTCCTTTCCTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTAT
TCTGGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGCATGCTGGGGATGCGGTGG
GCTCTATGGAACCAGCTG；
In SEQUENCE NO.21,
chimeric intron
AACGCAGTCAGTGCTCGACTGATCACAGGTAAGTATCAAGGTTACAAGACAGGTTTAAGGAGGCCAATAGAAACTGG
GCTTGTCGAGACAGAGAAGATTCTTGCGTTTCTGATAGGCACCTATTGGTCTTACTGACATCCACTTTGCCTTTCTC
TCCACAGGGGTACCGAAGCCGCTAGCGCTACCGGTC；
In SEQUENCE NO.22,
Linker1
GGCGGCGGAGGCAGCGGCGGCGGAGGCAGCGGCGGCGGAGGCAGC；
In SEQUENCE NO.23,
Linker2
GGCGGCGGAGGCAGCGGCGGCGGAGGCAGCGGCGGAGGCGGATCC；
In SEQUENCE NO.24,
Linker3
GTCGAAGGTGGAAGTGGAGGTTCTGGTGGAAGTGGAGGTTCAGGTGGAGTTGAC；
2) described BsAb antibody genes expression cassette is inserted to the attB of p2 Ф C31 empty carriers or pMC.BESXP empty carriers
Between attP sites, specific steps include A) or B) in it is any：
A)
PCT application (the application number that specific steps were submitted with reference to inventor in 2014：PCT/CN2014/083741) explanation
Book：
Embodiment 1 be " a kind of minicircle dna restructuring matrix grain p2 Ф C31.Bab's of expression casette containing genetic engineering antibody
Construction method ", it is micro- to the p2 Ф C31 with coding GPC3 × CD3BsAb antibody nucleotide sequences for obtaining the embodiment of the present invention 2
Ring matrix grain；And
A kind of " the minicircle dna restructuring matrix grain pMC.Bab of expression casette containing the genetic engineering antibody structure of embodiment 6
The step of method "；GPC3 × CD3BsAb antibody nucleotide sequences are encoded to having for the embodiment of the present invention 2 is obtained
PMC.BESXP micro-loop matrix grains.
Step 1-2 of the present invention) place different from above-mentioned PCT application be only that, the step 1-2 of the embodiment of the present invention 2) will be upper
State " BiTE gene order " in PCT application embodiment 1 or 6 replace with the embodiment of the present invention 2 " GPC3 × CD3BsAb's
Gene order ".
B)
The method for directly using digestion-connection, two digestions of SmaI-ApaI are designed at BsAb antibody gene expression cassettes both ends
Site and pMC.BESXP empty carriers or p2 Ф C31 empty carriers, pass through digestion-connection by the BsAb antibody genes expression cassette of synthesis
Mode insert between p2 Ф C31 empty carriers or attB the and attP sites of pMC.BESXP empty carriers；It is real that the present invention is obtained respectively
Apply the p2 Ф C31 micro-loop matrix grains or pMC.BESXP micro-loop matrix grains with coding BsAb antibody nucleotide sequences of example 1.
The plasmid map of pMC.BESXP micro-loop matrix grains prepared by the embodiment of the present invention 1 (is named as p- as shown in Figure 1
GPC3×CD3)。
Embodiment 2
The structure of minicircle dna with coding GPC3 × CD3BsAb antibody nucleotide sequences
PCT application (the application number submitted with reference to inventor in 2014：PCT/CN2014/083741) specification：
Embodiment 2 and embodiment 7 " a kind of preparation method of the minicircle dna of expression casette containing genetic engineering antibody ", point
Not to the minicircle dna with coding GPC3 × CD3BsAb antibody nucleotide sequences for obtaining the embodiment of the present invention 2.
The place different from above-mentioned PCT application embodiment 2 and embodiment 7 of the invention is only that the embodiment of the present invention 3 will be upper
State the micro-loop matrix grain that the micro-loop matrix grain in PCT application embodiment 2 or 7 replaces with the offer of the embodiment of the present invention 1.
Micro-loop collection of illustrative plates prepared by the embodiment of the present invention 2 is as shown in Figure 2.
Embodiment 3
The expression and purifying of BsAb antibody, comprise the following steps：
(1) expression of GPC3 × CD3BsAb antibody in HEK 293T cells
Using X-treme GENEHP DNA Transfection Reagent plasmid transfections kits (Roche companies)
By minicircle dna (minicircle dna prepared by the grain of micro-loop matrix shown in Fig. 2) transfection HEK293T cells of embodiment 3, HEK293T cells
GPC3BsAb micro-loops carrier is transfected after 72 hours, GPC3BsAb antibody in Western Blot detection culture medium supernatant cytoplasm
Expression, fruit is as shown in figure 3, BsAb-1, BsAb-2 and BsAb-3 cytoplasm have expression；BsAb-1, BsAb-2 have secretion
Expression, wherein BsAb-1 secreting, expressings amount highest.
(2) purifying of GPC3 × CD3BsAb antibody
Gauge mould transfects HEK 293T cells in the GPC3BsAb micro-loop carriers that will have secreting, expressing, collects culture supernatant,
Used again using His-Tag affine resins purifying (His-Tag Purification Resin, Roche), antibody after purification
ELISA method detection protein concentration；Protein concentration is adjusted to 1.0mg/ml after purification, is placed in -80 DEG C long-term preservation, is ready for use on stream
Formula cell art is detected and external knurl of killing is tested.
Embodiment 4
Flow cytometry GPC3 × CD3BsAb-1, GPC3 × CD3BsAb-2 antibody and Jurkat, HepG2 cell
Binding activity, comprise the following steps：
A) cell culture：Jurkat cell (1640medium；Suspension growth, the cell line of CD3 expression)；HEPG2(DMEM
medium；The liver cancer cell lines of GPC3 expression),
B) pancreatin digestion HepG2, add serum-containing media neutralize after centrifugation abandon supernatant and obtain cell；Jurkat is suspension cell
Cell directly is collected by centrifugation；
C) tears are washed 2 times with precooling PBS, 200g centrifugation 5min, collects cell, count respectively；
D) mean allocation is per experimental group 1 × 105Individual/group sample, is grouped as follows：
Jurkat cell, 2 groups:Blank group (the supernatant after Blank, pMC.BESXP empty carrier transfection HEK 293T cells；
Prepare in advance)；GPC3 × CD3BsAb groups (the antibody of the gained of embodiment 3 after purification；Prepare in advance)
HepG2 cells, 2 groups:It is grouped as above, the Kong Baizu ＆GPC3BsAb groups (antibody of the gained of embodiment 3 after purification；In advance
Prepare) Jurkat, 2 groups:It is grouped as above, blank group and the GPC3 × CD3BsAb groups (antibody of the gained of embodiment 3 after purification；In advance
Prepare)
E) the above-mentioned μ l/ groups of supernatant 100 are added and is incubated 30min on ice；
F) 1ml precoolings PBS washings are added, 200g centrifugation 5min, cell is collected, adds prior precooling and the APC- diluted
The μ l (1 of PBS 100 of mouse anti-6His antibody:1000 dilutions), 30min is incubated on ice,
G) 1ml precoolings PBS washings are added, 200g centrifugation 5min, collect cell, then be resuspended with 200 μ l PBS.Up flow type is thin
Born of the same parents' instrument (BD C6) observation combines situation.
Fig. 4 is the flow cytomery result of BsAb combination CD3 positive cells (Jurkat)；Fig. 5 combines for BsAb
The flow cytomery result of GPC3 antigen-positive cells (HepG2).In Fig. 4 and Fig. 5, C curve is blank group；B curves are
BsAb experimental groups.Experimental result shows that only BsAb-1 has CD3 cells and the two-way binding function of target cell, and BsAb-2 only has
Part target cell binding function.
Embodiment 5
The antibody combined DCIK cell killings HepG2 cell experiments of GPC3 × CD3BsAb
Target cell (T) is HepG2 cells in this example；Effector cell (E) is the DCIK cells (cell of BMDC regulation
The killing cell of factor induction, dendritic cell activated and cytokine induced killer
Cell), kill knurl experiment and use commercial kit CytoTox 96Non-Radioactive Cytotoxicity Assay
(Promega companies, cat.G1780)
Step reference reagent box specification, it is specific as follows：
A) trypsin digestion collects cultured target cell (HepG2), after counting, is resuspended in the DMEM cultures containing 5%FBS
In base, according to 2 × 104It is grouped, is inoculated into 96 orifice plates in/hole and Fig. 6.
B) centrifugal process is collected effector cell DCIK (E) and counted, and is resuspended in the DMEM culture mediums containing 5%FBS, presses respectively
According to E:T=4:1 and E:T=8:1 ratio, added according to packet in middle Fig. 6 in corresponding hole.
C) each BsAb (refined solution is diluted to 1ug/ml, i.e. 1ng/ul) is added according to Fig. 6, addition is 10ng/ holes, 10
μ l, one group is set to compare (DCIK groups) without BsAb, every group of 4 multiple holes；
D) 37 DEG C of cell culture incubators be incubated 3 hours 15 points；
E) maximum release lactic dehydrogenase (LDH) hole of target cell adds 10 μ l lysates, mixes；
F) 37 DEG C of cell culture incubators continue after being incubated 45 minutes, and 96 hole 250g are centrifuged 4 minutes, shift each hole supernatants of 10 μ l
Into 96 new orifice plates, then each hole adds 50 μ l LDH substrate solutions, is incubated at room temperature 30 minutes；
G) each hole adds 50 μ l terminate liquid, and absorbance is determined at 490nm.
H) according to absorbance, calculated according to formula below and kill knurl efficiency：
Kill knurl efficiency (%)=[(EBsAb-Espon-Tspon)/(Tmax-Tspon)]×100
Wherein, EBsAbRepresent each experimental group release lactic dehydrogenase (LDH)；EsponRepresent the spontaneous release LDH of effector cell；
TsponRepresent target cell spontaneous release LDH, TmaxRepresent the maximum release LDH of target cell.(according to practical illustration book, the porose number of institute
Culture medium ground control is subtracted according to before processing, experimental group subtracts volume correction value).
The result of joint DCIK cell killing HepG2 cell experiments is as shown in Figure 7.
In the figure 7, the longitudinal axis represents to kill the relative value of ratio of outflow；Abscissa represents different groups and effect target ratio (E:T).
As shown in Figure 7, compared with independent DCIK groups (no BsAb groups), add GPC3 × CD3BsAb and kill ratio of outflow raising,
It is best that wherein GPC3 × CD3BsAb-1 kills knurl effect, in effect target ratio (E:T it is) 4:1 and 8:When 1, respectively up to 45.39%,
75.76%, illustrate that GPC3 × CD3BsAb-1 specific can mediate DCIK (primary T cell) to kill target cell.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
All any modification, equivalent and improvement made within refreshing and principle etc., should be included in the scope of the protection.With
Upper described is only presently preferred embodiments of the present invention, is not intended to limit the invention, it is all the spirit and principles in the present invention it
Interior made all any modification, equivalent and improvement etc., should be included in the scope of the protection.
Claims (10)
1. the double targeting antibodies of a species specificity, it is characterised in that the double targeting antibodies of specificity have specificity and mankind CD3
With reference to the first antigen-binding domains and specificity and the second antigen-binding domains of GPC3 antigen bindings.
2. the double targeting antibodies of specificity as claimed in claim 1, it is characterised in that the double targeting antibodies of specificity are included extremely
The LCVR amino of the HCVR amino acid sequences of few first antigen-binding domains, at least one the first antigen-binding domains
Acid sequence, the HCVR amino acid sequences of at least one the second antigen-binding domains and at least one the second antigen binding knots
The LCVR amino acid sequences in structure domain；Wherein, the HCVR and LCVR are respectively HCVR and LCVR amino acid sequences optional in table 1
Row.
3. the double targeting antibodies of a species specificity are applied by following one or more methods：
(1) the double targeting antibodies of the specificity are individually applied；
(2) by the double targeting antibodies of the specificity and the one or more in chemotherapy, radiotherapy, operation, biological therapy, immunization therapy
Use in conjunction；
(3) the double targeting antibodies of the specificity are directly delivered into patient's body by the way of delivering in vivo to be treated；
(4) first pass through in-vitro transfection technology to mix the double targeting antibodies of the specificity with immune effector cell, then by described in
The defeated time patient's body of immune effector cell for being mixed with specific double targeting antibodies implements treatment.
4. a kind of pharmaceutical composition, including at least one double targeting antibodies of specificity as claimed in claim 1, and diagnosticum,
Pharmaceutically useful supporting agent, excipient or diluent.
A kind of 5. nucleic acid molecules, it is characterised in that the amino acid sequence of the double targeting antibodies of coding specificity as claimed in claim 1
Row.
6. a kind of recombinant vector, it is characterised in that there is any sequence of nucleic acid molecules as claimed in claim 7.
7. recombinant vector as claimed in claim 6, it is characterised in that the recombinant vector is expression vector or minicircle dna.
8. a kind of host cell, it is characterised in that include recombinant vector as claimed in claim 6.
9. a kind of antibody drug, it is characterised in that be the double targeting antibodies of any specificity as claimed in claim 1, with the mankind
CD3 is combined, and in the killing carried out to GPC3 positive cells of external evoked T cell mediation.
10. specificity pair targeting antibodies as claimed in claim 1 or such as recombinant vector as claimed in claim 6 are examined in preparation
Break, prevent, the application in the reagent or medicine for the treatment of GPC3 diseases.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610514296.8A CN107556387A (en) | 2016-06-30 | 2016-06-30 | Resisting GPC 3 and the double targeting antibodies of CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610514296.8A CN107556387A (en) | 2016-06-30 | 2016-06-30 | Resisting GPC 3 and the double targeting antibodies of CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107556387A true CN107556387A (en) | 2018-01-09 |
Family
ID=60969057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610514296.8A Pending CN107556387A (en) | 2016-06-30 | 2016-06-30 | Resisting GPC 3 and the double targeting antibodies of CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107556387A (en) |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109402168A (en) * | 2018-10-30 | 2019-03-01 | 深圳新诺微环生物科技有限公司 | Bridging molecules and its application of minicircle dna expression connection HER2 positive cell and effector cell |
| CN110551222A (en) * | 2019-08-27 | 2019-12-10 | 重庆市畜牧科学院 | Novel bifunctional antibody and application thereof |
| CN112010982A (en) * | 2020-08-31 | 2020-12-01 | 重庆金迈博生物科技有限公司 | anti-GPC 3/CD3 bispecific antibody and application thereof |
| CN114126649A (en) * | 2019-06-10 | 2022-03-01 | 中外制药株式会社 | anti-T cell antigen binding molecules for use in combination with cytokine inhibitors |
| CN114246944A (en) * | 2020-09-24 | 2022-03-29 | 盛禾(中国)生物制药有限公司 | Pharmaceutical composition of bispecific antibody and application thereof |
| CN114539416A (en) * | 2020-11-26 | 2022-05-27 | 盛禾(中国)生物制药有限公司 | Chromatographic purification process of bispecific antibody |
| WO2022117050A1 (en) * | 2020-12-02 | 2022-06-09 | 康诺亚生物医药科技（成都）有限公司 | Development of new tumor engager therapeutic drug and use thereof |
| CN115160440A (en) * | 2022-06-15 | 2022-10-11 | 复旦大学 | Novel bispecific antibodies |
| CN115698072A (en) * | 2020-07-01 | 2023-02-03 | 山东博安生物技术股份有限公司 | anti-GPC 3 antibody, anti-GPC 3 chimeric antigen receptor, and GPC3/CD3 bispecific antibody |
| WO2023045151A1 (en) * | 2021-09-24 | 2023-03-30 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against gpc3 and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102216333A (en) * | 2008-11-21 | 2011-10-12 | 伊莱利利公司 | C-met antibodies |
| CN103833852A (en) * | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | Bispecific antibody aiming at phosphatidylinositols protein polysaccharide-3 and T cell antigen |
| CN104520331A (en) * | 2012-06-01 | 2015-04-15 | 美国政府(由卫生和人类服务部的部长所代表) | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| CN105658235A (en) * | 2013-08-23 | 2016-06-08 | 宏观基因有限公司 | Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof |
-
2016
- 2016-06-30 CN CN201610514296.8A patent/CN107556387A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102216333A (en) * | 2008-11-21 | 2011-10-12 | 伊莱利利公司 | C-met antibodies |
| CN104520331A (en) * | 2012-06-01 | 2015-04-15 | 美国政府(由卫生和人类服务部的部长所代表) | High-affinity monoclonal antibodies to glypican-3 and use thereof |
| CN103833852A (en) * | 2012-11-23 | 2014-06-04 | 上海市肿瘤研究所 | Bispecific antibody aiming at phosphatidylinositols protein polysaccharide-3 and T cell antigen |
| CN105658235A (en) * | 2013-08-23 | 2016-06-08 | 宏观基因有限公司 | Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109402168A (en) * | 2018-10-30 | 2019-03-01 | 深圳新诺微环生物科技有限公司 | Bridging molecules and its application of minicircle dna expression connection HER2 positive cell and effector cell |
| CN114126649A (en) * | 2019-06-10 | 2022-03-01 | 中外制药株式会社 | anti-T cell antigen binding molecules for use in combination with cytokine inhibitors |
| CN110551222B (en) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | Novel bifunctional antibody and application thereof |
| CN110551222A (en) * | 2019-08-27 | 2019-12-10 | 重庆市畜牧科学院 | Novel bifunctional antibody and application thereof |
| CN115698072B (en) * | 2020-07-01 | 2023-07-04 | 山东博安生物技术股份有限公司 | anti-GPC 3 antibody, anti-GPC 3 chimeric antigen receptor and GPC3/CD3 bispecific antibody |
| CN115698072A (en) * | 2020-07-01 | 2023-02-03 | 山东博安生物技术股份有限公司 | anti-GPC 3 antibody, anti-GPC 3 chimeric antigen receptor, and GPC3/CD3 bispecific antibody |
| CN112010982A (en) * | 2020-08-31 | 2020-12-01 | 重庆金迈博生物科技有限公司 | anti-GPC 3/CD3 bispecific antibody and application thereof |
| CN112010982B (en) * | 2020-08-31 | 2023-06-27 | 重庆金迈博生物科技有限公司 | anti-GPC 3/CD3 bispecific antibody and application thereof |
| CN114246944A (en) * | 2020-09-24 | 2022-03-29 | 盛禾(中国)生物制药有限公司 | Pharmaceutical composition of bispecific antibody and application thereof |
| CN114539416A (en) * | 2020-11-26 | 2022-05-27 | 盛禾(中国)生物制药有限公司 | Chromatographic purification process of bispecific antibody |
| WO2022117050A1 (en) * | 2020-12-02 | 2022-06-09 | 康诺亚生物医药科技（成都）有限公司 | Development of new tumor engager therapeutic drug and use thereof |
| WO2023045151A1 (en) * | 2021-09-24 | 2023-03-30 | Zhejiang Shimai Pharmaceutical Co., Ltd. | Antibodies against gpc3 and uses thereof |
| CN115160440A (en) * | 2022-06-15 | 2022-10-11 | 复旦大学 | Novel bispecific antibodies |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107556387A (en) | Resisting GPC 3 and the double targeting antibodies of CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application | |
| CN105949325B (en) | Chimeric antigen receptor, slow virus carrier and its application comprising CD27 intracellular domain | |
| TW202023613A (en) | Anti-claudin182 antibody and use thereof | |
| CN109072199A (en) | Target the Chimeric antigen receptor and application thereof of Fc receptor sample 5 | |
| EP3940076A1 (en) | Robo1 car-nk cell carrying suicide gene, preparation method therefor and application thereof | |
| CN106810610A (en) | Anti-EpCAM and the double targeting antibodies of CD3 specificity and its preparation method and application, the minicircle dna containing this pair of targeting antibodies expression cassette and application | |
| CN106543288A (en) | A kind of application in the T cell preparation of mesothelin Chimeric antigen receptor modification and treatment of pancreatic cancer | |
| MXPA04011624A (en) | Neutralizing human anti-igfr antibody. | |
| CN109913422A (en) | A kind of immunocyte comprising tumour antigen identification receptor and its application | |
| CN113416260B (en) | Claudin18.2-targeted specific chimeric antigen receptor cell and preparation method and application thereof | |
| CN101970472A (en) | Rtef-1 variants and the use thereof for inhibition of angiogenesis | |
| CN113788894A (en) | Monoclonal antibody of targeted human Claudin18.2 protein and application thereof | |
| US11857572B2 (en) | Method for preparing CAR-T cell with TCM as main active component and use thereof | |
| CN116874608A (en) | Chimeric antigen receptor | |
| CN109423495A (en) | A kind of pair of targeting Chimeric antigen receptor and application thereof | |
| CN108728465A (en) | A kind of minicircle dna carrier and its preparation method and application of expression target cell-effector cell's bridge | |
| CN104887717A (en) | Immunity enhancing reagent | |
| CN114835781B (en) | WTN polypeptide and application thereof in detection and treatment of cancer | |
| KR20190117681A (en) | Bispecific Antibodies That Bind HER3 and CD3 | |
| CN107556386A (en) | Anti- EGFRvIII and CD3 specificity double targeting antibodies, the minicircle dna containing double targeting antibodies expression cassettes and applications | |
| CN107573416A (en) | The double targeting antibodies of anti-IGF1R and CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application | |
| CN102532269B (en) | Dominant sequence of delta 1 chain complementary determining region (CDR) 3 in gamma delta T lymphocytes, and T cell receptor (TCR) transfected cells and application thereof | |
| CN106810611A (en) | Double targeting antibodies of anti-cMet and CD3 specificity and its preparation method and application, the minicircle dna containing this pair of targeting antibodies expression cassette and application | |
| CN106349391A (en) | HBV specific double-targeted antibody as well as preparation method and application thereof, minicircle DNA containing double-targeted antibody expression box and application of minicircle DNA | |
| CN111205361B (en) | Interleukin 21 protein (IL21) mutant and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180109 |
|
| RJ01 | Rejection of invention patent application after publication |